| CAS NO: | 292605-14-2 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 1mg | 询价 |
| 2mg | 询价 |
| 5mg | 询价 |
| 10mg | 询价 |
| 25mg | 询价 |
| 50mg | 询价 |
| 100mg | 询价 |
| 250mg | 询价 |
| 500mg | 询价 |
| Molecular Weight (MW) | 306.40 |
|---|---|
| Formula | C15H14O3S2 |
| CAS No. | 292605-14-2 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 61 mg/mL (199.1 mM) |
| Water:<1 mg/mL | |
| Ethanol: 10 mg/mL (32.6 mM) | |
| Solubility (In vivo) | 4% DMSO+corn oil: 10 mg/mL |
| Synonyms | SB3CT; SB3-CT; SB-3CT; Chemical Name: 2-(((4-phenoxyphenyl)sulfonyl)methyl)thiirane InChi Key: LSONWRHLFZYHIN-UHFFFAOYSA-N InChi Code: InChI=1S/C15H14O3S2/c16-20(17,11-14-10-19-14)15-8-6-13(7-9-15)18-12-4-2-1-3-5-12/h1-9,14H,10-11H2 SMILES Code: O=S(CC1SC1)(C2=CC=C(OC3=CC=CC=C3)C=C2)=O |
| In Vitro | In vitro activity: SB-3CT directly inhibits bone marrow endothelial cell invasion and tubule formation in Matrigel in vitro. Cell Assay: PC3 cells are seeded in 35-mm dishes (5×104 cells/dish) in complete culture medium. The next day, the medium is replaced with complete medium supplemented with 1% DMSO alone (vehicle) or SB-3CT (final concentrations 0.1-50 μM) in 1% DMSO. At various times, the cells are harvested with trypsin and counted. |
|---|---|
| In Vivo | In L-CI.5s T-cell lymphoma model, SB-3CT (5-50 mg/kg/d i.p.) potently inhibit liver metastasis and increases survival of mice. SB-3CT (50 mg/kg/d i.p.) inhibits human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model. In a mouse model of embolus-induced “permanent” focal cerebral ischemia, SB-3CT counteracts degradation of neuronal laminin, protects neurons from ischemic cell death, and ameliorates neurobehavioral outcomes after embolic MCA occlusion. |
| Animal model | Mouse L-CI.5s T-cell lymphoma model |
| Formulation & Dosage | Dissolved in 10% DMSO.; 50 mg/kg; i.p. injection |
| References | Cancer Res. 2005 May 1;65(9):3523-6; Int J Cancer. 2006 Jun 1;118(11):2721-6. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |